Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KLK7 | P49862 | 2/20 | 0.50 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753462 | 0.97 | MAPT (0.62) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL13938297 | 0.96 | HTT (0.65) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL26773396 | 0.95 | MAPT (0.60) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL3478848 | 0.94 | MAPT (0.59) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL13480435 | 0.93 | MAPT (0.65) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL15679441 | 0.92 | MAPT (0.64) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL13090607 | 0.92 | MAPT (0.64) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL20385193 | 0.92 | MAPT (0.64) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL14010425 | 0.91 | HTT (0.59) | HTTMAPTSYKLMNASMN1; SMN2 | |
| SCHEMBL31490150 | 0.91 | MAPT (0.53) | HTTMAPTSYKLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2012-11-29 | — | — | US | disclosed |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2012-11-29 | — | — | US | disclosed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-8258259-B2 | Macromolecular compounds having controlled stoichiometry | STARPHARMA PTY LIMITED (AU) | 2012-09-04 | — | — | US | disclosed |
| US-20090324535-A1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LTD (AU) | 2009-12-31 | — | — | US | disclosed |
| US-20090324535-A1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LTD (AU) | 2009-12-31 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | STARPHARMA PTY LIMITED (AU) | 2009-05-07 | — | — | US | disclosed |
| WO-2007082331-A1 | MODIFIED MACROMOLECULE | STARPHARMA PTY LIMITED (AU) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007048190-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | STARPHARMA PTY LIMITED (AU) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | HTT 32/4885MAPT 946/4885SYK 4851/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | HTT 2931/4885MAPT 3927/4885SYK 3467/4885 |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | POLI, POLR2A, POLR2B | HTT 2078/4885MAPT 3594/4885SYK 3464/4885 |
| US-20090118467-A1 | Macromolecular Compounds Having Controlled Stoichiometry | MICA, PICALM, CLTB | HTT 1106/4885MAPT 97/4885SYK 189/4885 |
| US-20120302730-A1 | MACROMOLECULAR COMPOUNDS HAVING CONTROLLED STOICHIOMETRY | MICA, PICALM, CLTB | HTT 1106/4885MAPT 97/4885SYK 189/4885 |
| US-20090324535-A1 | MODIFIED MACROMOLECULE | MRPL11, MAX, MRPL38 | HTT 2938/4885MAPT 1971/4885SYK 1076/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | HTT 2475/4885MAPT 2305/4885SYK 2903/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | HTT 53/4885MAPT 3053/4885SYK 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.